Welcome to our quarterly update relating to biologics and biosimilars, including post-grant and patent litigation challenges to blockbuster biologics. This past quarter as COVID spread across the globe, challenges to patents covering branded biologics seemed to cool down as well as biosimilar approvals. Since enactment of the BPCIA, 29 biosimilars have been approved, 16 of which have launched. This past quarter saw the approval of only one biosimilar – Riabni, a rituximab biosimilar marketed by Amgen.
Please see full publication below for more information.
